Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
80 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Severe Psoriasis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Severe Psoriasis - Pipeline Review, H2 2014', provides an overview of the Severe Psoriasis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Severe Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Severe Psoriasis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Severe Psoriasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Severe Psoriasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Severe Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Severe Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Severe Psoriasis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Severe Psoriasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Severe Psoriasis Overview 7 Therapeutics Development 8 Pipeline Products for Severe Psoriasis - Overview 8 Pipeline Products for Severe Psoriasis - Comparative Analysis 9 Severe Psoriasis - Therapeutics under Development by Companies 10 Severe Psoriasis - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Severe Psoriasis - Products under Development by Companies 14 Severe Psoriasis - Companies Involved in Therapeutics Development 15 Johnson & Johnson 15 Boehringer Ingelheim GmbH 16 Amgen Inc. 17 Eli Lilly and Company 18 Merck & Co., Inc. 19 ApoPharma Inc. 20 Novartis AG 21 Pfizer Inc. 22 Idera Pharmaceuticals, Inc. 23 Almirall, S.A. 24 Syntrix Biosystems, Inc. 25 Vascular Biogenics Ltd. 26 Severe Psoriasis - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Target 28 Assessment by Mechanism of Action 30 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 36 brodalumab - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 ixekizumab - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 secukinumab - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 tildrakizumab - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 LAS-41008 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 adalimumab biosimilar - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 baricitinib - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 VB-201 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 aminopterin sodium - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 orilotimod - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 BI-655066 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 IMO-8400 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 PF-04965842 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 AMG-811 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 guselkumab - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Severe Psoriasis - Recent Pipeline Updates 59 Severe Psoriasis - Dormant Projects 75 Severe Psoriasis - Discontinued Products 76 Severe Psoriasis - Product Development Milestones 77 Featured News & Press Releases 77 Mar 28, 2012: Amgen Announces Publication Of Phase II Study Results Of Brodalumab For Treatment Of Psoriasis In New England Journal Of Medicine 77 Appendix 79 Methodology 79 Coverage 79 Secondary Research 79 Primary Research 79 Expert Panel Validation 79 Contact Us 80 Disclaimer 80
List of Tables Number of Products under Development for Severe Psoriasis, H2 2014 8 Number of Products under Development for Severe Psoriasis - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 11 Comparative Analysis by Late Stage Development, H2 2014 12 Comparative Analysis by Clinical Stage Development, H2 2014 13 Products under Development by Companies, H2 2014 14 Severe Psoriasis - Pipeline by Johnson & Johnson, H2 2014 15 Severe Psoriasis - Pipeline by Boehringer Ingelheim GmbH, H2 2014 16 Severe Psoriasis - Pipeline by Amgen Inc., H2 2014 17 Severe Psoriasis - Pipeline by Eli Lilly and Company, H2 2014 18 Severe Psoriasis - Pipeline by Merck & Co., Inc., H2 2014 19 Severe Psoriasis - Pipeline by ApoPharma Inc., H2 2014 20 Severe Psoriasis - Pipeline by Novartis AG, H2 2014 21 Severe Psoriasis - Pipeline by Pfizer Inc., H2 2014 22 Severe Psoriasis - Pipeline by Idera Pharmaceuticals, Inc., H2 2014 23 Severe Psoriasis - Pipeline by Almirall, S.A., H2 2014 24 Severe Psoriasis - Pipeline by Syntrix Biosystems, Inc., H2 2014 25 Severe Psoriasis - Pipeline by Vascular Biogenics Ltd., H2 2014 26 Assessment by Monotherapy Products, H2 2014 27 Number of Products by Stage and Target, H2 2014 29 Number of Products by Stage and Mechanism of Action, H2 2014 31 Number of Products by Stage and Route of Administration, H2 2014 33 Number of Products by Stage and Molecule Type, H2 2014 35 Severe Psoriasis Therapeutics - Recent Pipeline Updates, H2 2014 59 Severe Psoriasis - Dormant Projects, H2 2014 75 Severe Psoriasis - Discontinued Products, H2 2014 76
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
